TFF3 and Barrett esophagus: The Barrett’s oESophagus Trial 3 (BEST3) showed that, in individuals with GERD, the offer of Cytosponge-TFF3 testing results in improved detection of BE compared with usual care (rate ratio of 10.6) [9].